| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.064 | 0.4 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.04 | 0.4 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.4 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.4 |